Loading stock data…
$4.42+0.19 (+4.49%)
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States.
Zura Bio Limited in the Healthcare sector is trading at $4.47 with a market capitalization of $516M. Wall Street consensus targets $18.00 (6 analysts), implying a +302.2% move over the next 12 months. The stock is currently 40% below its 52-week high of $7.44, remaining 15.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$29.32M↓ | -$25.50M↓ | -$18.41M↑ | -$19.52M↓ | -$18.06M |
| Net Income | -$26.30M↓ | -$24.22M↓ | -$17.18M↑ | -$18.04M↓ | -$15.99M |
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody enginee...